drugset / Trial / NCT03366974
Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers
NaSingle-groupOpen-labelBasic science
Summary
The study objective is to evaluate and validate of endogenous markers for the assessment of change in CYP3A activity by route of administration in Korean healthy subjects using metabolomics. In addition, we aim to screen novel endogenous marker, which could determine the total or intestinal CYP activity.
Timeline
- Start
- 2017-12-28
- Primary completion
- 2018-02-13
- Completion
- 2018-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Subject | Midazolam | Small molecule | 1 mg | Intravenous |
| Subject | Midazolam | Small molecule | 5 mg | Intravenous |
Indications
No indication recorded.